Trial Name: EMBRACE: A clinical research study testing olaparib, in Homologous recombination (HR) deficient metastatic breast and relapsed ovarian cancer in patients who do not have hereditary mutations in BReast CAncer susceptibility gene 1 and gene 2 (BRCA1 and BRCA2) (ACTRN12617000855325).
Patients Involved: Adults with Triple negative breast cancer or High grade serous ovarian cancer.
Treatment Given: All study participants will take olaparib 300 mg orally twice daily until disease progression or unacceptable toxicity. Assessments for safety and efficacy will be followed up for a minimum of 6 months.
Rationale for Treatment: Olaparib, has been approved overseas and in Australia in women shown to have inherited changes in their BRCA1 or 2 genes. There is strong evidence to show that olaparib will also work in people who have non-inherited changes in their BRCA1 or 2 genes, or particular changes in other genes. The purpose of this study is to assess whether olaparib is effective in treating these tumours.
Recruitment: The trial opened in November 2017. The aim is to recruit 60 patients over a 36 month period.
Sites involved: Participating sites are located in New South Wales, Victoria, Queensland, South Australia and Western Australia.
For additional information and contact details, please click here:
All correspondence should be directed to the EMBRACE Trial Coordinator: embrace@ctc.usyd.edu.au or 02 9562 5000.